ACE2 News and Research

RSS

The role of inhibiting palmitoylation of the SARS-CoV-2 spike protein on viral infectivity

It is demonstrated that palmitoylation of the first five cysteine residues of the C-terminal domain of the SARS-CoV-2 spike protein facilitates cell entry and the formation of syncytia.

11 Oct 2021

Delta variant exhibits immune evasion, enhanced cell entry, and augmented syncytium formation

Researchers addressed the question of using reporter particles pseudotyped with the S protein of SARS-CoV-2, which are suitable tools to examine SARS-CoV-2 neutralization antibodies.

11 Oct 2021

The neurological effects of COVID-19

What is the relationship between COVID-19 and the brain? A new review published in Tropical Biomedicine summarizes the key findings on how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes severe COVID-19 infection, disrupts brain activity and produces a range of long-term neurological disorders.

10 Oct 2021

Phase I clinical trial of two Cuban recombinant protein COVID-19 vaccines

The results of Phase I clinical trials for two new COVID-19 vaccine candidates based on recombinant RDB proteins are reported.

10 Oct 2021

What impact does temperature have on SARS-CoV-2 M protein dynamics?

In a recent study, the structural dynamics of the SARS-CoV-2 M protein are studied at temperatures of 10-50 ˚C using molecular dynamics simulations.

10 Oct 2021

Lipids, COVID-19, and host immunity

A new study from a team of researchers at the University of Pennsylvania examines the role played by lipids in this disease.

10 Oct 2021

Powerful neutralizing antibody against SARS-CoV-2 variants of concern

A new paper discusses a new antibody with potent neutralizing activity against the ancestral SARS-CoV-2 strain, as well as newer variants of SARS-CoV-2.

10 Oct 2021

Role of S-acylation in SARS-CoV-2 infectivity

A new study published in Developmental Cell investigates S-acylation of the SARS-CoV-2 S protein.

10 Oct 2021

Study supports efficacy and safety of lung-selective nanotherapy against SARS-CoV-2 infection

A new preprint shows the potential role of a host protease cathepsin L inhibitor, which mediates viral entry into the host cell by its effect on the viral spike protein.

8 Oct 2021

mRNA vaccination associated with decreased risk of COVID-19 infection and hospitalization in U.S. veterans

Researchers from the U.S. Veterans Affairs have examined the U.S. effort to vaccinate its Veteran population to investigate further.

8 Oct 2021

Assay to assess and quantify presence of RBD-directed antibodies against SARS-CoV-2 following vaccination

Researchers from Roche Diagnostics have been testing a new assay known as the Elecsys assay.

8 Oct 2021

non-RBD mutation in SARS-CoV-2 variants enhances resistance to neutralizing antibodies

Researchers from Ohio State University have been investigating mutations in the rest of the spike protein, particularly the Q677H mutation.

7 Oct 2021

Scientists develop a cell-free assay to screen SARS-CoV-2 entry inhibitors

Scientists have developed and validated a cell-free fluorescence assay for the rapid screening of protein inhibitors.

7 Oct 2021

Novel proteomics approach predicts severe COVID-19 outcomes

Researchers in the United States, Canada, and the UK have developed a potential new approach to predicting severe and critical outcomes among patients with coronavirus disease 2019 (COVID-19).

6 Oct 2021

Graphene biosensor in a portable and wireless device for rapid SARS-CoV-2 detection

A new study posted to the medRxiv* server and led by Dr. Mattia D'Agostino, Dr. Eleonora Pavoni and Dr. Alice Romagnoli from the Polytechnic University of Marche in Ancona (Italy), a gFET biosensor that uses angiotensin-converting enzyme 2 (ACE2) as a bioreceptor has been put forth as a viable solution.

6 Oct 2021

SARS-CoV-2 emerging variants display enhanced syncytia formation

Researchers compared the replication and syncytia forming potential of Alpha, Beta, and D614G strains in human cell lines and primary airway cells.

6 Oct 2021

Study shows lower SARS-CoV-2 infection rates in smokers

Coronavirus disease 2019 (COVID-19) primarily infects the lungs, later spreading through the bloodstream. The worst prognoses are mostly seen in ‘at-risk’ groups, such as the immunocompromised, elderly, or those suffering from respiratory conditions.

6 Oct 2021

Cysteamine inhibits SARS-CoV-2 variants of concern in vitro

Researchers in the United States have shown that a compound currently used to treat cystinosis exhibits broad antiviral activity against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 Oct 2021

Plasmid DNA vaccines induce effective antibody responses against SARS-CoV-2 in mice

Researchers in the United States and China have developed plasmid DNA immunogens that induce effective antibody responses in mice against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 Oct 2021

SARS-CoV-2 beta variant elicits variant specific and cross-reactive antibodies

One recent study assessed the serum of Beta variant infected patients to determine whether major non-VOC antibodies could neutralize this virus.

5 Oct 2021

ACE2 News and Research

The role of inhibiting palmitoylation of the SARS-CoV-2 spike protein on viral infectivity

Delta variant exhibits immune evasion, enhanced cell entry, and augmented syncytium formation

The neurological effects of COVID-19

Phase I clinical trial of two Cuban recombinant protein COVID-19 vaccines

What impact does temperature have on SARS-CoV-2 M protein dynamics?

Lipids, COVID-19, and host immunity

Powerful neutralizing antibody against SARS-CoV-2 variants of concern

Role of S-acylation in SARS-CoV-2 infectivity

Study supports efficacy and safety of lung-selective nanotherapy against SARS-CoV-2 infection

mRNA vaccination associated with decreased risk of COVID-19 infection and hospitalization in U.S. veterans

Assay to assess and quantify presence of RBD-directed antibodies against SARS-CoV-2 following vaccination

non-RBD mutation in SARS-CoV-2 variants enhances resistance to neutralizing antibodies

Scientists develop a cell-free assay to screen SARS-CoV-2 entry inhibitors

Novel proteomics approach predicts severe COVID-19 outcomes

Graphene biosensor in a portable and wireless device for rapid SARS-CoV-2 detection

SARS-CoV-2 emerging variants display enhanced syncytia formation

Study shows lower SARS-CoV-2 infection rates in smokers

Cysteamine inhibits SARS-CoV-2 variants of concern in vitro

Plasmid DNA vaccines induce effective antibody responses against SARS-CoV-2 in mice

SARS-CoV-2 beta variant elicits variant specific and cross-reactive antibodies

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News